OPRX Boosts DSP Revenue Potential While Navigating Near-Term Headwinds
This article discusses how OPRX is increasing its DSP revenue potential. It also touches on the company's efforts to navigate various near-term challenges.
OptimizeRx Stock Down 30% in a Month: Should Investors Hold or Fold?
OptimizeRx (OPRX) stock has fallen 30.4% in the last month, underperforming industry benchmarks and competitors due to macroeconomic challenges and changing customer spending habits. The company lowered its 2026 revenue guidance, citing limited visibility and a decline in contracted revenue. Despite these headwinds, OptimizeRx improved profitability metrics in Q1, with adjusted EBITDA more than doubling due to cost optimization and growth in its AI-enabled DAAP platform and subscription services, while also strengthening its long-term outlook through strategic platform expansion and improved financial flexibility.
OptimizeRx Stock Down 30% in a Month: Should Investors Hold or Fold?
OptimizeRx stock has fallen 30% in the past month, underperforming its industry and the S&P 500. The company faces challenges including macroeconomic pressures, cautious customer spending, and customer-specific execution issues, leading to a downward revision of its 2026 revenue guidance. Despite these headwinds, OptimizeRx improved profitability through cost optimization and is seeing momentum in its AI-enabled platform and subscription offerings, but its current Zacks Rank is a "Sell."
OptimizeRx Corp stock (US6837631027): earnings momentum and buyback plan put focus back on digital h
OptimizeRx Corp (OPRX) recently reported better-than-expected quarterly earnings and announced a new share buyback program, bringing renewed attention to the digital health company. The company surpassed consensus estimates with EPS of $0.14 and revenue of $19.84 million. OptimizeRx operates a digital health network connecting pharmaceutical manufacturers, payers, and healthcare providers, leveraging its platform-based model to integrate with EHR systems and monetize access for life sciences companies.
OptimizeRx (OPRX) CCO logs Form 4 tax-withholding share dispositions
OptimizeRx Chief Commercial Officer Theresa Greco reported routine tax-related share dispositions via two Form 4 filings. On May 15, 2026, the company withheld 879 and 914 shares of Common Stock at $5.21 per share to cover her tax obligations upon the vesting of restricted stock units. These transactions, totaling 1,793 shares, are not open-market sales but standard equity-compensation tax treatments, leaving Greco with over 71,000 shares.
OptimizeRx (OPRX) CEO has 5,219 shares withheld to cover RSU tax
OptimizeRx CEO Stephen L. Silvestro had 5,219 shares of common stock withheld by the company on May 15, 2026, to cover tax withholding obligations related to the vesting of restricted stock units. This transaction, valued at $5.21 per share, is considered a disposition under Section 16 rules but was not an open-market sale. After this, Silvestro directly owned 185,288 shares of OptimizeRx common stock.
OptimizeRx's Q4 Beat: A Closer Look at the Numbers
OptimizeRx (OPRX) reported strong Q4 and full-year 2025 financial results, exceeding estimates with record net income and adjusted EBITDA. However, the company's cautious 2026 guidance, citing a shift away from managed services and client spending conservatism due to MFN pricing uncertainties, led to a significant stock sell-off. Despite near-term challenges, OptimizeRx is strategically poised to leverage long-term digital health trends, including AI and the booming specialty medication market, particularly GLP-1s, presenting a potential long-term opportunity for patient investors.
OptimizeRx (Nasdaq:OPRX) - Stock Analysis
This Simply Wall St report provides a detailed analysis of OptimizeRx (OPRX), highlighting its current stock performance, valuation metrics, and recent news. The company is trading significantly below its estimated fair value, with analysts forecasting strong earnings growth, despite recent volatility in its share price. Recent updates include revised earnings guidance, new product launches, and changes to its board and executive team.
OptimizeRx Corp stock (US6837631027): earnings beat, buyback plan and volatile AI-health rally
OptimizeRx Corp (OPRX) reported stronger-than-expected Q1 2026 earnings and announced a $10 million stock buyback program, despite its shares having fallen more than 50% year-to-date. The company, focused on AI-powered digital health solutions, aims to leverage its technology to connect pharmaceutical manufacturers with healthcare providers through electronic health records. Analysts maintain a "Moderate Buy" rating, with an average price target of $13.43, reflecting both confidence in its growth potential and recognition of execution risks in a volatile market for small-cap technology stocks.
OptimizeRx Corp (NASDAQ:OPRX) Beats Q1 Estimates But Slashes 2026 Revenue Guidance
OptimizeRx Corp (NASDAQ:OPRX) exceeded Q1 revenue and EPS estimates but saw its shares decline due to a slashed 2026 revenue guidance. The company reported $19.8 million in revenue and $0.14 non-GAAP EPS, yet reduced its full-year 2026 revenue forecast to $95 million to $100 million, citing pricing dynamics and macroeconomic factors. Despite this, OptimizeRx completed debt refinancing and initiated efficiency measures, maintaining its adjusted EBITDA guidance.
OptimizeRx Cuts Revenue Outlook: Will Pressures Ease Ahead?
OptimizeRx (OPRX) has lowered its 2026 revenue outlook to $95-$100 million from an earlier projection of $109-$114 million, citing macroeconomic uncertainty and client budget tightening. Despite this, the company reported encouraging underlying business trends, including 60% growth in its Dynamic Audience Activation Platform and solid 110% net revenue retention, with expectations of momentum improving in 2027. Rivals GoodRx (GDRX) and Doximity (DOCS) are also navigating similar market pressures, with GoodRx revising its revenue guidance upward and Doximity facing soft digital pharma advertising markets.
OptimizeRx Corp stock (US6837631027): Bank note points to valuation reset
OptimizeRx Corp (OPRX) is under renewed focus after a valuation-focused note highlighted stronger financial performance and a more favorable outlook for the stock. The company, which specializes in digital healthcare marketing, saw an upgrade to a strong-buy view from MarketsMojo. While the stock has shown short-term volatility, its core business model relies on enterprise spending in the healthcare sector, making its performance sensitive to pharma marketing budgets and new product launches.
Stifel cuts OptimizeRx stock price target on weaker guidance
Stifel lowered its price target for OptimizeRx Corp. from $17 to $14 while maintaining a Buy rating. The adjustment follows a modest first-quarter revenue and earnings beat but a 13% reduction in the company's annual revenue guidance due to a customer-specific issue and broader industry headwinds. OptimizeRx expects to mitigate the revenue impact with cost actions and anticipates a more favorable outlook for 2027 as current issues anniversary.
OptimizeRx (NASDAQ: OPRX) cuts Q1 loss as margins improve and debt refinanced
OptimizeRx significantly narrowed its Q1 2026 net loss to $495,000 from $2.2 million in the prior year, primarily by improving margins despite a 10% decrease in net revenue to $19.8 million. This improvement was driven by a strategic shift away from low-margin managed service programs and a reduction in overall expenses. The company also refinanced its long-term debt, securing a new $25 million term loan and a $10 million revolving facility at a lower interest rate to replace a previous loan with a 19.5% effective interest.
Stifel cuts OptimizeRx stock price target on weaker guidance By Investing.com
Stifel has lowered its price target for OptimizeRx (NASDAQ:OPRX) from $17 to $14 but maintained a Buy rating, citing weaker annual revenue guidance. Despite a slight beat in Q1 revenue and earnings, the digital health company reduced its guidance by 13% due to a customer-specific issue and economic uncertainties, though it maintained its 2026 EBITDA guidance through cost-cutting measures. OptimizeRx's DAAP revenue grew 60% year-over-year, and its subscription revenue increased by 45%.
OptimizeRx Corporation (NASDAQ:OPRX) Q1 2026 Earnings Call Transcript
OptimizeRx Corporation reported Q1 2026 earnings, beating expectations with an EPS of $0.14 against a $0.01 expectation. Despite macroeconomic headwinds and a more cautious budget allocation from some clients, resulting in a revised full-year revenue guidance of $95 million to $100 million, the company maintained its adjusted EBITDA guidance of $21 million to $25 million by implementing cost optimization initiatives. OptimizeRx is also expanding its platform capabilities, including programmatic access for DSPs to its EHR network, which is expected to drive significant growth in 2027.
OptimizeRx Corporation Stock 12‑Month Price Target Cut to $14, Implies 121% Upside
OptimizeRx Corporation's average 12-month price target has been lowered from $14.5 to $11.83 by analysts, implying an 87% potential upside based on the closing price. Despite the cut, the consensus rating remains "Buy" among 7 analysts, with 6 recommending a Buy and 1 a Hold. Investors can find more detailed analyst data on the Forecasts tab and track recommendations in the News Flow section.
OptimizeRx debt deal expected to save $1.5M a year in interest
OptimizeRx reported Q1 2026 revenue of $19.8 million, a 10% year-over-year decrease, with a GAAP net loss of $0.5 million. Despite the revenue dip, the company saw improved non-GAAP net income and adjusted EBITDA. OptimizeRx also refinanced its debt, expecting to save $1.5 million annually in interest, and initiated efficiency measures aiming for $3 million in annualized savings.
OptimizeRx Expands EHR Advertising Reach With New DSP Integration
OptimizeRx Corporation has expanded its EHR advertising capabilities by integrating its proprietary electronic health record network with demand-side platforms (DSPs). This integration allows life sciences marketers to access authenticated EHR advertising inventory directly through programmatic buying workflows, enabling precise targeting at the point of care and seamless inclusion of EHR placements in broader omnichannel marketing strategies. The company aims to provide bot-free inventory to healthcare professionals within their clinical workflow and expects this move to open new opportunities in the $19 billion pharmaceutical digital advertising market.
OptimizeRx Corp. (OPRX) surpasses Q1 earnings and revenue estimates
OptimizeRx Corp. (OPRX) exceeded first-quarter earnings and revenue expectations, reporting an adjusted EPS of $0.09 against an estimated $0.06, and revenue of $18.9 million compared to a projected $18.49 million. Despite this strong performance, the company's shares are down over 25% year-to-date, contrasting with the S&P 500's rise. Investors will be watching for further guidance and future performance indicators.
Earnings call transcript: OptimizeRx Q1 2026 beats estimates, stock rises
OptimizeRx Corp (OPRX) reported its first-quarter 2026 earnings, significantly surpassing EPS and revenue forecasts. The company posted an EPS of $0.14 against a forecast of $0.01, and revenue of $19.8 million exceeded the $18.86 million forecast. OptimizeRx's stock rose by 2.42% following the announcement, driven by strong operational performance, a strategic shift to subscription-based models, and cost optimization, despite a 10% year-over-year revenue decline.
OptimizeRx (Nasdaq: OPRX) posts Q1 2026 results and secures $35M credit facility
OptimizeRx (OPRX) reported its Q1 2026 financial results, showing a 10% decrease in revenue to $19.8 million year-over-year, but significantly narrowed its GAAP net loss to $0.5 million and increased non-GAAP net income and adjusted EBITDA. The company also secured a new $35 million senior secured credit facility with Fifth Third Bank, which is expected to save $1.5 million annually in interest expenses due to a 625 basis point rate reduction. Additionally, OptimizeRx updated its full-year 2026 revenue guidance to $95-$100 million and maintained its adjusted EBITDA guidance of $21-$25 million, while implementing further operating efficiency initiatives targeting $3 million in annualized savings.
OptimizeRx Expands EHR Advertising Reach With New DSP Integration
OptimizeRx (OPRX) has introduced a new connection between its EHR network and demand-side platforms (DSPs), allowing life sciences marketers to programmatically access EHR advertising. This integration enables advertisers to target healthcare professionals within their clinical workflow more efficiently and expands OptimizeRx's presence in the programmatic advertising ecosystem. The company believes this will help DSPs capture a larger share of the pharmaceutical digital advertising market.
OptimizeRx Corp. Sees Valuation Upgrade Amid Positive Financial Trends and High Institutional Confidence
OptimizeRx Corp. has received an upgraded valuation from "attractive" to "very attractive" based on its financial performance. Despite a recent stock decline, the company exhibits strong financial indicators like a P/E ratio of 123 and a PEG ratio of 1.22, along with significant profit growth and 100% institutional ownership, highlighting strong investor confidence. This adjustment signals a favorable outlook for OptimizeRx within the software products sector.
Pharma ads go programmatic inside doctors' EHRs via OptimizeRx
OptimizeRx (Nasdaq: OPRX) has launched a new programmatic connection that links its EHR network directly with demand-side platforms (DSPs). This innovation allows life sciences media buyers to activate authenticated, point-of-care EHR campaigns at scale within existing programmatic workflows, tapping into a market estimated at 90% of total U.S. digital display ad spend and the $19B+ pharma digital ad market. The initiative aims to provide faster campaign activation, self-managed reach and frequency for EHR placements, and seamless integration into omnichannel strategies for marketers while giving DSPs previously unavailable access to authenticated EHR inventory.
OptimizeRx Launches Programmatic Access to Authenticated EHR Advertising at Scale
OptimizeRx Corporation has launched a new programmatic connection point that allows DSPs to directly integrate with its EHR network, enabling life sciences marketers to access authenticated EHR advertising at scale. This development bridges the gap between high-impact EHR campaigns and programmatic efficiency, allowing media buyers to activate campaigns faster, manage reach, and incorporate EHR advertising into their omnichannel strategies. It also provides DSPs with a competitive advantage in the life sciences market by offering previously unavailable authenticated EHR inventory.
Should You Add OPRX Stock to Your Portfolio Pre-Q1 Earnings?
OptimizeRx (OPRX) is set to report its Q1 2026 earnings on May 12, with analysts expecting a significant year-over-year decline in both earnings and revenue due to a slower start to the year and industry-specific dynamics. Despite a predicted earnings miss based on Zacks' model, the company has shown strong historical earnings surprises and maintains a positive long-term outlook, particularly with its Dynamic Audience Activation Platform and adjusted EBITDA guidance. Investors are advised to await the earnings call for further commentary.
Should You Add OPRX Stock to Your Portfolio Pre-Q1 Earnings?
OptimizeRx Corporation (OPRX) is slated to report its Q1 2026 earnings on May 12, with consensus estimates predicting a significant year-over-year revenue decrease and a smaller profit. The company's earnings model does not predict a beat, citing challenges like conservative client spending and a market shift from managed services. Despite near-term volatility and a stock plunge, OptimizeRx remains optimistic about its long-term platform traction, AI integration, and cost discipline, suggesting existing investors wait for the earnings call while new investors seek a more favorable entry point.
Should You Add OPRX Stock to Your Portfolio Pre-Q1 Earnings?
OptimizeRx Corporation (OPRX) is set to report its Q1 2026 earnings on May 12, with consensus estimates predicting a significant drop in EPS and revenues year-over-year due to macro headwinds and industry shifts. Despite a history of beating earnings estimates, Zacks' model does not predict an earnings beat this quarter given a negative Earnings ESP. While the company faces near-term volatility and reduced visibility, strong EBITDA guidance, and traction with its Dynamic Audience Activation Platform offer a positive long-term outlook, suggesting existing investors await the earnings call and new investors seek a better entry point.
OptimizeRx (OPRX) Projected to Post Earnings on Tuesday
OptimizeRx (OPRX) is projected to release its Q1 2026 earnings on Tuesday, May 12th, with analysts expecting diluted EPS of $0.01 and revenue of $18.353 million. The company's board recently authorized a $10.0 million share buyback, and institutional investors hold a significant portion of its stock. Despite recent trading down to $6.59, analysts have a "Moderate Buy" consensus rating with a $17.57 price target.
OptimizeRx ESG report counts supply-chain emissions for first time
OptimizeRx (Nasdaq: OPRX) has released its 2026 Environmental, Social, and Governance (ESG) report, detailing key advancements in its corporate responsibility. For the first time, the report includes Scope 3 supply chain emissions in its greenhouse gas reporting, expanding on disclosures that began in 2022. Additionally, the company appointed Mary Varghese Presti as an independent director to its Board, bringing over 25 years of experience in healthcare, life sciences, and technology.
OPRX SEC Filings - Optimizerx Corp 10-K, 10-Q, 8-K Forms
This page provides access to Optimizerx (OPRX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, and 8-K material events, along with AI-powered summaries and impact analysis. Recent filings covered executive compensation, Q2 2025 financial results showing significant revenue growth, and a change in the board of directors. The platform offers detailed financial insights and regulatory document access for investors.
[ARS] OptimizeRx Corp SEC Filing
OptimizeRx Corp (OPRX) filed an ARS document with the SEC on April 30, 2026, at 7:16 AM. This filing is classified with low impact and neutral sentiment. The full document is available as a PDF viewer and on SEC EDGAR.
OptimizeRx Releases 2026 Environmental, Social, and Governance (ESG) Report
OptimizeRx Corp. has published its 2026 Environmental, Social, and Governance (ESG) report, highlighting key advancements in its corporate citizenship. The report features the appointment of Mary Varghese Presti as an independent director to its Board and the inclusion of Scope 3 supply chain emissions in its greenhouse gas reporting for the first time. OptimizeRx remains committed to aligning its mission with ESG responsibilities while leveraging AI-driven healthcare technology to improve patient outcomes.
OptimizeRx Releases 2026 Environmental, Social, and Governance (ESG) Report
OptimizeRx has published its 2026 Environmental, Social, and Governance (ESG) Report, detailing its commitment to sustainability, social responsibility, and ethical governance practices. The report outlines the company's strategies and performance in these key areas, reinforcing its dedication to corporate responsibility.
OptimizeRx Sets First Quarter 2026 Conference Call for May 12, 2026, at 4:30 P.m. ET
OptimizeRx will host a conference call on May 12, 2026, at 4:30 PM ET to discuss its first-quarter 2026 results. The call will also include a business update and outlook. Investors can access the live webcast or a replay following the event.
OptimizeRx Sets First Quarter 2026 Conference Call for May 12, 2026, at 4:30 p.m. ET
OptimizeRx Corporation (Nasdaq: OPRX) has announced it will host a conference call on Tuesday, May 12, 2026, at 4:30 p.m. Eastern Time. The call is to discuss its financial results for the first quarter ended March 31, 2026. Prior to the call, a press release detailing these results will be issued.
OptimizeRx Sets First Quarter 2026 Conference Call for May 12, 2026, at 4:30 p.m. ET
OptimizeRx Corp. (Nasdaq: OPRX) has announced a conference call for Tuesday, May 12, 2026, at 4:30 p.m. Eastern Time to discuss its first-quarter 2026 financial results. The financial results will be released via press release before the call. Management will host the call, followed by a Q&A session, and details for participation are provided, including toll-free and international numbers, a conference ID, and webcast link.
OptimizeRx Sets First Quarter 2026 Conference Call for May 12, 2026, at 4: 30 p.m. ET
OptimizeRx Corp. (Nasdaq: OPRX) has announced it will host a conference call on Tuesday, May 12, 2026, at 4:30 p.m. Eastern Time. The purpose of the call is to discuss the company's financial results for the first quarter period ended March 31, 2026, which will be released in a press statement prior to the call. A replay of the call will be available on the OptimizeRx website for 12 months.
OptimizeRx will post quarterly results before a May 12 investor call
OptimizeRx (Nasdaq: OPRX) has scheduled a conference call for May 12, 2026, at 4:30 p.m. Eastern Time to discuss its first-quarter results, which ended March 31, 2026. The company will release its financial results in a press release prior to the call. A replay of the call will be available for 12 months on the OptimizeRx investor website.
OptimizeRx (OPRX) Price Target Increased by 24.79% to 24.82
The article reports that the price target for OptimizeRx (OPRX) has been increased by 24.79% to $24.82. This indicates a positive outlook from analysts on the company's future stock performance.
OptimizeRx vs. GoodRx: Which Digital Health Stock is the Better Buy?
This article compares OptimizeRx (OPRX) and GoodRx (GDRX), two digital health companies, to determine which presents a stronger investment opportunity. It analyzes their fundamentals, growth prospects, market challenges, and valuations. Based on Zacks Rank and valuation, OptimizeRx currently appears to be the better choice despite some revenue headwinds.
OptimizeRx vs. GoodRx: Which Digital Health Stock is the Better Buy?
This article compares OptimizeRx (OPRX) and GoodRx (GDRX), two digital health companies, to determine which offers a better investment opportunity. While OptimizeRx benefits from AI adoption and a focus on margin stability, GoodRx leverages a strong consumer platform and pharma manufacturer solutions. The analysis delves into their fundamentals, growth prospects, market challenges, and valuations, with OptimizeRx ultimately being favored due to its strong Zacks Rank and better valuation.
OptimizeRx vs. GoodRx: Which Digital Health Stock is the Better Buy?
This article compares OptimizeRx (OPRX) and GoodRx (GDRX), two digital health stocks, to determine which presents a stronger investment opportunity. It evaluates their fundamentals, growth prospects, market challenges, and valuations, concluding that OptimizeRx is the better buy due to its higher Zacks Rank, favorable valuation, and upward analyst estimate revisions, despite some near-term revenue challenges. GoodRx faces headwinds from variable prescription transaction revenues and declining telehealth and subscription growth.
Will Enterprise Deals & MedTech Momentum Fuel OPRX's Growth Engine?
OptimizeRx (OPRX) is strategically positioned for growth by securing large enterprise deals and capitalizing on the expanding MedTech market. The company has seen success with AI-driven engagement platforms, expanding pilot programs into multi-brand strategies, and is gaining traction in the MedTech sector. Despite strong competitive pressure from larger players like Doximity (DOCS) and Veeva Systems (VEEV), OptimizeRx's financial outlook, including an upward revision of its fiscal 2026 earnings estimate, places it as a Zacks Rank #1 (Strong Buy) stock.
OptimizeRx Corp. (NASDAQ:OPRX) Receives Average Recommendation of "Moderate Buy" from Brokerages
OptimizeRx Corp. (NASDAQ:OPRX) has an average "Moderate Buy" rating from nine analysts, with an average target price of $17.57, despite several recent price target cuts. The company's board has authorized a $10.0 million share buyback, and institutional investors hold 76.47% of the stock. Shares are trading around $6.80, with a P/E of 26.15 and a market capitalization of approximately $127.6 million.
New OptimizeRx Corp (OPRX) director registers insider status with Form 3
OptimizeRx Corp director Presti Mariyamma Varghese has filed an initial Form 3, signaling her status as a new insider for the company. This regulatory filing serves to establish beneficial ownership for new directors and does not indicate any current share holdings or transactions. The Form 3 confirms Varghese's role as a director, setting a baseline for future reporting of her potential insider activities.
Can OptimizeRx's Cash Strength Cushion Near-Term Headwinds?
OptimizeRx (OPRX) is leveraging its strong cash position, increasing profitability, and expanding client relationships to navigate immediate challenges. Despite facing near-term headwinds like softer contracted revenue and cautious pharmaceutical client spending, the company's financial flexibility and disciplined execution are expected to drive a recovery, particularly in the latter half of 2026. OptimizeRx also raised its adjusted EBITDA guidance for 2026 and announced a share repurchase program.
OPRX Trades at a Discount to Industry: How to Approach the Stock Now?
OptimizeRx (OPRX) is currently trading at a significant discount compared to its industry peers and the broader Zacks Computer & Technology sector, despite strong 2025 revenue growth and improved cash generation. The company is strategically positioned in the digital health sector with AI poised to boost its value proposition, and management shows confidence through a share repurchase program. However, near-term challenges like market volatility and shifting pharma spending have led to a reduced 2026 revenue forecast, though long-term demand remains strong and earnings estimates are on an upward trend.
Medical robotics firm Myomo taps ex-OptimizeRx chief for board seat
Myomo, Inc. (NYSE American: MYO), a wearable medical robotics company, announced the appointment of William "Will" Febbo to its board of directors, effective April 14, 2026. Mr. Febbo, former CEO of OptimizeRx Corporation, brings over 30 years of experience in healthcare, financial services, and technology, having significantly scaled OptimizeRx's revenue and market capitalization. His expertise in direct-to-patient healthcare solutions and capital markets is expected to benefit Myomo's strategic growth and market awareness.
